Beta-blockers in heart failure: promising or proved?

Department of Medicine, University of Auckland School of Medicine, New Zealand.

Despite recent improvements in the management of congestive heart failure, the prognosis of many patients with this condition remains poor. The level of neurohormonal activation appears to be predictive of survival, and clinical studies indicate that inhibition of overactivated neurohormonal systems may be beneficial. Activation of the renin-angiotensin-aldosterone system is well documented in heart failure, and angiotensin-converting enzyme inhibition now has an established role in treatment based on evidence of hemodynamic, symptomatic and mortality benefit. Sympathetic nervous system activation also occurs as a compensatory mechanism in heart failure but with long-term deleterious effects. Increasing evidence suggests that beta-adrenergic blockade can produce hemodynamic and symptomatic improvement in heart failure of idiopathic or ischemic etiology. Trials of beta-adrenergic blocking agents in patients after myocardial infarction suggest a beneficial effect on mortality, even among those with heart failure. However, there remains uncertainty as to how generalizable are the results from the postinfarction trials, particularly in the current therapeutic environment with routine angiotensin-converting enzyme inhibitor therapy. Appropriately powered randomized, controlled trials are required to determine precisely the balance of benefit and risk resulting from long-term beta-blocker therapy in patients with heart failure of ischemic and other etiology.

This article has been cited by other articles:

				L. Balling, M. Schou, L. Videbaek, P. Hildebrandt, H. Wiggers, F. Gustafsson, and for the Danish Heart Failure Clinics Network Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure Eur J Heart Fail, September 1, 2011; 13(9): 968 - 973. [Abstract] [Full Text] [PDF]

				A Di Lenarda, R De Maria, A Gavazzi, D Gregori, M Parolini, G Sinagra, L Salvatore, F Longaro, E Bernobich, and F Camerini Long term survival effect of metoprolol in dilated cardiomyopathy Heart, April 1, 1998; 79(4): 337 - 344. [Abstract] [Full Text]

				J E Sanderson, S K W Chan, C M Yu, L Y C Yeung, W M Chan, K Raymond, K W Chan, and K S Woo beta Blockers in heart failure: a comparison of a vasodilating beta  blocker with metoprolol Heart, January 1, 1998; 79(1): 86 - 92. [Abstract] [Full Text] [PDF]

				P. Lechat, S. Escolano, J. L. Golmard, H. Lardoux, S. Witchitz, J. A. Henneman, B. Maisch, M. Hetzel, P. Jaillon, J.-P. Boissel, et al. Prognostic Value of Bisoprolol-Induced Hemodynamic Effects in Heart Failure During the Cardiac Insufficiency BIsoprolol Study (CIBIS) Circulation, October 7, 1997; 96(7): 2197 - 2205. [Abstract] [Full Text]

				M. Packer, W. S. Colucci, J. D. Sackner-Bernstein, C.-s. Liang, D. A. Goldscher, I. Freeman, M. L. Kukin, V. Kinhal, J. E. Udelson, M. Klapholz, et al. Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure: The PRECISE Trial Circulation, December 1, 1996; 94(11): 2793 - 2799. [Abstract] [Full Text]

				W. S. Colucci, M. Packer, M. R. Bristow, E. M. Gilbert, J. N. Cohn, M. B. Fowler, S. K. Krueger, R. Hershberger, B. F. Uretsky, J. A. Bowers, et al. Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure Circulation, December 1, 1996; 94(11): 2800 - 2806. [Abstract] [Full Text]

				E. J. Eichhorn and M. R. Bristow Medical Therapy Can Improve the Biological Properties of the Chronically Failing Heart: A New Era in the Treatment of Heart Failure Circulation, November 1, 1996; 94(9): 2285 - 2296. [Abstract] [Full Text]

				B. M. Massie, S. G. Fisher, P. C. Deedwania, B. N. Singh, R. D. Fletcher, and S. N. Singh Effect of Amiodarone on Clinical Status and Left Ventricular Function in Patients With Congestive Heart Failure Circulation, June 15, 1996; 93(12): 2128 - 2134. [Abstract] [Full Text]

				J. D. Sackner-Bernstein and D. M. Mancini Rationale for Treatment of Patients With Chronic Heart Failure With Adrenergic Blockade JAMA, November 8, 1995; 274(18): 1462 - 1467. [Abstract] [PDF]

				Effects of Carvedilol, a Vasodilator -Blocker, in Patients With Congestive Heart Failure Due to Ischemic Heart Disease Circulation, July 15, 1995; 92(2): 212 - 218. [Abstract] [Full Text]

				S. Saito, Y. Hiroi, Y. Zou, R. Aikawa, H. Toko, F. Shibasaki, Y. Yazaki, R. Nagai, and I. Komuro beta -Adrenergic Pathway Induces Apoptosis through Calcineurin Activation in Cardiac Myocytes J. Biol. Chem., October 27, 2000; 275(44): 34528 - 34533. [Abstract] [Full Text] [PDF]